270 related articles for article (PubMed ID: 15486518)
21. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.
Montgomery SA; Sheehan DV; Meoni P; Haudiquet V; Hackett D
J Psychiatr Res; 2002; 36(4):209-17. PubMed ID: 12191625
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.
Stein MB; Pollack MH; Bystritsky A; Kelsey JE; Mangano RM
Psychopharmacology (Berl); 2005 Jan; 177(3):280-8. PubMed ID: 15258718
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
Rickels K; Pollack MH; Sheehan DV; Haskins JT
Am J Psychiatry; 2000 Jun; 157(6):968-74. PubMed ID: 10831478
[TBL] [Abstract][Full Text] [Related]
24. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.
Merideth C; Cutler AJ; She F; Eriksson H
Int Clin Psychopharmacol; 2012 Jan; 27(1):40-54. PubMed ID: 22045039
[TBL] [Abstract][Full Text] [Related]
26. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
Bielski RJ; Ventura D; Chang CC
J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
[TBL] [Abstract][Full Text] [Related]
27. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
Perugi G; Frare F; Toni C; Ruffolo G; Torti C
Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
[TBL] [Abstract][Full Text] [Related]
28. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
Sheehan DV
J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
[TBL] [Abstract][Full Text] [Related]
29. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
[TBL] [Abstract][Full Text] [Related]
30. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
[TBL] [Abstract][Full Text] [Related]
31. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
Nicolini H; Bakish D; Duenas H; Spann M; Erickson J; Hallberg C; Ball S; Sagman D; Russell JM
Psychol Med; 2009 Feb; 39(2):267-76. PubMed ID: 18485261
[TBL] [Abstract][Full Text] [Related]
32. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
33. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies.
Pollack MH; Meoni P; Otto MW; Simon N; Hackett D
J Clin Psychopharmacol; 2003 Jun; 23(3):250-9. PubMed ID: 12826987
[TBL] [Abstract][Full Text] [Related]
34. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.
Lenox-Smith AJ; Reynolds A
Br J Gen Pract; 2003 Oct; 53(495):772-7. PubMed ID: 14601352
[TBL] [Abstract][Full Text] [Related]
35. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
Baldwin DS; Schweizer E; Xu Y; Lyndon G
Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
[TBL] [Abstract][Full Text] [Related]
36. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
Wang G; Gislum M; Filippov G; Montgomery S
Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
[TBL] [Abstract][Full Text] [Related]
37. Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR.
Rickels K; Etemad B; Rynn MA; Lohoff FW; Mandos LA; Gallop R
Psychother Psychosom; 2013; 82(6):363-71. PubMed ID: 24061331
[TBL] [Abstract][Full Text] [Related]
38. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial.
Hartford J; Kornstein S; Liebowitz M; Pigott T; Russell J; Detke M; Walker D; Ball S; Dunayevich E; Dinkel J; Erickson J
Int Clin Psychopharmacol; 2007 May; 22(3):167-74. PubMed ID: 17414743
[TBL] [Abstract][Full Text] [Related]
39. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
40. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder.
Rickels K; Mangano R; Khan A
J Clin Psychopharmacol; 2004 Oct; 24(5):488-96. PubMed ID: 15349004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
